Lane Tinsley, MD
Neurology · Oklahoma City, OKNPI 1558705038
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,430 of the $18,464 with a category attached, or 72.7%. UCB, Inc. accounts for 82.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $10,503 and has fallen 98.1% since, to $200 in 2025.
Across 167 payments — averaging $110.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$15K
- AbbVie$762
- Teva Pharmaceuticals USA, Inc.$418
- Amgen$362
- Novartis$242
- Biohaven Pharmaceuticals, Inc.$230
- plus $1K from 23 others
What the payments were for
- Consulting fees$1,4108%
- Speaking & faculty fees$13,43073%
- Travel & lodging$3142%
- Food & beverage$3,20917%
- Education$1021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 24 | $15,309 |
| AbbVie(2 entities) | 45 | $762 |
| Teva Pharmaceuticals USA, Inc. | 15 | $418 |
| Amgen | 13 | $362 |
| Novartis | 6 | $242 |
| Biohaven Pharmaceuticals, Inc. | 4 | $230 |
| Lundbeck LLC | 7 | $173 |
| Lilly USA, LLC | 11 | $164 |
| Genentech USA, Inc. | 7 | $140 |
| Merz Pharmaceuticals, LLC | 5 | $104 |
| SK Life Science, Inc. | 3 | $68 |
| Argenx US, Inc. | 3 | $67 |
| Upsher-smith Laboratories LLC | 2 | $53 |
| Neurocrine Biosciences, Inc. | 3 | $45 |
| Sanofi | 2 | $38 |
| Johnson & Johnson | 2 | $33 |
| Biogen | 2 | $32 |
| Acadia Pharmaceuticals Inc | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Eisai Inc. | 1 | $24 |
| TG Therapeutics, Inc. | 1 | $22 |
| Livanova USA, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Sarepta Therapeutics, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,464 in reported general payments places this provider in the 80th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$158K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.